CUAMC
China Universal Asset Management Company’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $406K | Buy |
80,269
+1,024
| +1% | +$5.18K | 0.04% | 257 |
|
|
2025
Q1 | $419K | Sell |
79,245
-1,698
| -2% | -$8.98K | 0.04% | 260 |
|
|
2024
Q4 | $547K | Buy |
80,943
+28,038
| +53% | +$190K | 0.05% | 242 |
|
|
2024
Q3 | $349K | Buy |
52,905
+25,851
| +96% | +$170K | 0.04% | 255 |
|
|
2024
Q2 | $203K | Sell |
27,054
-16,602
| -38% | -$125K | 0.03% | 243 |
|
|
2024
Q1 | $435K | Buy |
43,656
+19,565
| +81% | +$195K | 0.06% | 196 |
|
|
2023
Q4 | $238K | Buy |
24,091
+18,854
| +360% | +$186K | 0.05% | 191 |
|
|
2023
Q3 | $40.1K | Buy |
5,237
+2,817
| +116% | +$21.6K | 0.01% | 242 |
|
|
2023
Q2 | $18.1K | Sell |
2,420
-65
| -3% | -$486 | 0.01% | 278 |
|
|
2023
Q1 | $16.6K | Buy |
2,485
+639
| +35% | +$4.26K | 0.01% | 240 |
|
|
2022
Q4 | $14.2K | Buy |
1,846
+299
| +19% | +$2.31K | 0.01% | 199 |
|
|
2022
Q3 | $16K | Buy |
+1,547
| New | +$16K | 0.01% | 168 |
|